<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756937</url>
  </required_header>
  <id_info>
    <org_study_id>238KOA12G</org_study_id>
    <nct_id>NCT01756937</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee</brief_title>
  <acronym>ABSOLUTE-R</acronym>
  <official_title>A Six-month, Multi Center, Randomizied, Double Blind, Parallel-group,Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of Imotun capsule in osteoarthritis of the knee
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A six-month, multi center, randomizied, double blind, parallel-group,placebo controlled
      study to evaluate efficacy and safety of Imotun capsule in osteoarthritis of the knee
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in the Lequesne's index score at 24weeks</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in the Lequesne's index score at 24weekS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>100mm Pain VAS</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessment of 100mm Pain VAS (24weekS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Lequesne's index score at 4weeks</measure>
    <time_frame>baseline, 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline Lequesne's index score at 4weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Lequesne's index score at 8weeks</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline Lequesne's index score at 8weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Lequesne's index score at 16weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline Lequesne's index score at 16weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm Pain VAS</measure>
    <time_frame>4weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Patient's assessment of 100mm Pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assement (Patient, Physician)</measure>
    <time_frame>4weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>-Global assement (Patient, Physician)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>administration days of the rescue medication</measure>
    <time_frame>24weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>administration days of the rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients who consumed the rescue medication</measure>
    <time_frame>24weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate of patients who consumed the rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm Pain VAS</measure>
    <time_frame>8weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Patient's assessment of 100mm Pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm Pain VAS</measure>
    <time_frame>16weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Patient's assessment of 100mm Pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm Pain VAS at 4weeeks</measure>
    <time_frame>baseline, 4weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>change from baseline 100mm Pain VAS at 4weeeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm Pain VAS at 8weeeks</measure>
    <time_frame>baseline, 8weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>change from baseline 100mm Pain VAS at 8weeeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm Pain VAS at 16weeeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>change from baseline 100mm Pain VAS at 16weeeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm Pain VAS at 24weeeks</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>change from baseline 100mm Pain VAS at 24weeeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assement (Patient, Physician)</measure>
    <time_frame>8weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>-Global assement (Patient, Physician)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assement (Patient, Physician)</measure>
    <time_frame>16weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>-Global assement (Patient, Physician)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Global assement (Patient, Physician)</measure>
    <time_frame>baseline, 16weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>-Global assement (Patient, Physician)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assement (Patient, Physician)</measure>
    <time_frame>24weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>-Global assement (Patient, Physician)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dosing quantity of the rescue medication</measure>
    <time_frame>24weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>dosing quantity of the rescue medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessed by the incidence of adverse event</measure>
    <time_frame>up to 24weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessed by the incidence of adverse event</description>
  </other_outcome>
  <other_outcome>
    <measure>laboratory test</measure>
    <time_frame>up to 24weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>laboratory test</description>
  </other_outcome>
  <other_outcome>
    <measure>medication history</measure>
    <time_frame>up to 24weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>medication history</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Imotun</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300.03mg/cap,orally, 1 capsule once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imotun</intervention_name>
    <description>300.03mg/cap,orally, 1 capsule once daily for 24 weeks</description>
    <arm_group_label>Imotun</arm_group_label>
    <other_name>Avocado-Soya Unsaponifiables 300.03mg/Cap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule once daily for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agreement with written informed consent and 40 years of age and older

          -  Patients with more than 63months history of OA of knee according to ACR criteria

          -  Radiographic evidence of Kellgren &amp; Lawrence grade II to III OA of the knee

          -  The 100mm Pain VAS is over 40mm

          -  The Lequensne's index is over 5

        Exclusion Criteria:

          -  Treatment with SYSADOA within 3 months

          -  History of joint surgery within 5 years or Arthroscopic surgery within 1year

          -  Intra-articular injections within 3 months

          -  Treatment with NASIDs within 7 days

          -  Any history of adverse reaction to the study drugs

          -  clinically significant hepatic, renal, cardiovascular diseases

          -  Patients with gastrointestinal ulcers or bleeding disorders

          -  Pregnant women, nursing mothers or Fertile women who not practice contraception with
             appropriate methods

          -  History of drug abuse or alcoholism

          -  Patients on any other clinical trial or experimental treatment in the past 4 weeks

          -  An impossible one who participates in clinical trial by investigator's decision
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Hyun Yoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dae Hyun Yoo</last_name>
    <phone>82-2-2290-9202</phone>
    <email>dhyoo@hanyang.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym Universicy Sacred heart Hospital</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Ah Kim, PhD</last_name>
      <phone>82-31-380-1826</phone>
      <email>baladeur@hallym.or.kr</email>
    </contact>
    <investigator>
      <last_name>Hyun Ah Kim, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A university Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam university medical center</name>
      <address>
        <city>Daegu</city>
        <zip>705-035</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choongki Lee, PhD</last_name>
      <phone>82-53-620-3841</phone>
      <email>cklee@med.yu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Choongko Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University hospital</name>
      <address>
        <city>Daejon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National university medical school &amp; Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Seok Lee, PhD</last_name>
      <phone>82-62-220-6590</phone>
      <email>shinseok@chonnam.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Shin Seok Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hanyang University Guri Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Soon Lee, PhD</last_name>
      <phone>82-31-560-2247</phone>
      <email>lhsberon@hanyang.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hye Soon Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajuo university hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>433-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Soo Song, PhD</last_name>
      <phone>82-2-6299-1409</phone>
      <email>drsong@cau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jung Soo Song, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SangHeon Lee, PhD</last_name>
      <phone>82-2-2030-7541</phone>
      <email>shlee@kuh.ac.kr</email>
    </contact>
    <investigator>
      <last_name>SangHeon Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Special City of Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daehyun Yoo, phD</last_name>
    </contact>
    <investigator>
      <last_name>DaeHyun Yoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 25, 2013</lastchanged_date>
  <firstreceived_date>October 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis of the knee</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
